CTX-M and TEM as Predominant Types of Extended Spectrum β-Lactamases Among Serratia marcescens Isolated From Solid Organ Recipients

Transplantation Proceedings

Volumn 41, Issue 8, 2009, Pages 3253-3255

  Mlynarczyk, A ^a   Szymanek, K ^a   Sawicka Grzelak, A ^a   Pazik, J ^a   Buczkowska, T ^a   Durlik, M ^a   Lagiewska, B ^a   Pacholczyk, M ^a   Chmura, A ^a   Paczek, L ^a   Mlynarczyk, G ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAMASE; BETA LACTAMASE CTX M; BETA LACTAMASE TEM 1; CEFOTAXIME; CEFPIROME; CEFPODOXIME; CEFTAZIDIME; CLAVULANIC ACID; EXTENDED SPECTRUM BETA LACTAMASE; UNCLASSIFIED DRUG;

ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATION; CONTROLLED STUDY; HOSPITAL INFECTION; HUMAN; MAJOR CLINICAL STUDY; NONHUMAN; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SERRATIA INFECTION; SERRATIA MARCESCENS;

ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; DNA PRIMERS; DRUG THERAPY, COMBINATION; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; HUMANS; POLYMERASE CHAIN REACTION; SERRATIA INFECTIONS; SERRATIA MARCESCENS; TRANSPLANTATION;

EID: 70350511849     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2009.08.011     Document Type: Article

References (8)

1. Yanagawa Y., Marumo K., Nakamura Y., et al. Isolation rate of non-hemagglutinating strains of Serratia marcescens from clinical specimens in a general hospital: comparison of serotypes O2 and O14. J Infect Chemother 13 (2007) 151
2. Buffet-Bataillon S., Rabier V., Bétrémieux P., et al. Outbreak of Serratia marcescens in a neonatal intensive care unit: contaminated unmedicated liquid soap and risk factors. J Hosp Infect 72 (2009) 17
3. Mlynarczyk A., Mlynarczyk G., Pupek J., et al. Serratia marcescens isolated in 2005 from clinical specimens from patients with diminished immunity. Transplant Proc 39 (2007) 2879
4. Crivaro V., Bagattini M., Salza M.F., et al. Risk factors for extended-spectrum beta-lactamase-producing Serratia marcescens and Klebsiella pneumoniae acquisition in a neonatal intensive care unit. Hosp Infect 67 (2007) 135
5. CLSI. Performance standards for antimicrobial susceptibility testing; 19th informational supplement. CLSI document M100-S19 (2009), Clinical and Laboratory Standarts Institute, Wayne, PA
6. Stürenburg E., Lang M., Horstkotte M.A., et al. Evaluation of the MicroScan ESBL plus confirmation panel for detection of extended-spectrum beta-lactamases in clinical isolates of oxyimino-cephalosporin-resistant Gram-negative bacteria. J Antimicrob Chemother 54 (2004) 870
7. Livermore D.M., Canton R., Gniadkowski M., et al. CTX-M: changing the face of ESBLs in Europe. J Antimicrob Chemother 59 (2007) 165
8. Naumiuk L., Baraniak A., Gniadkowski M., et al. Molecular epidemiology of Serratia marcescens in two hospitals in Gdańsk, Poland, over a 5-year period. J Clin Microbiol 42 (2004) 3108 [Erratum in J Clin Microbiol 42:391, 2004]